Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Zhong Yao Cai ; 32(4): 564-7, 2009 Apr.
Artigo em Chinês | MEDLINE | ID: mdl-19645243

RESUMO

OBJECTIVE: To study the effect of paeonol on protecting endothelial cells of diabetic rats. METHODS: Streptozocin was used on rats to make diabetic models. Different dosages of paeonol were fed on all the model rats. PGI, TXA2, ET, CRP, ICAM-1, VCAM-1 and NO were tested after 30 day's therapy. RESULTS: Compared with control group PGI increased from 89.75 +/- 2.75, 89.97 +/- 7.28, 89.97 +/- 11.36 to 120.03 +/- 13.85, 108.34 +/- 11.25, 105.32 +/- 8.85, respectively. TXA2 decreased from 157.64 +/- 10.36, 156.64 +/- 11.35, 153.33 +/- 19.40 to 124.46 +/- 18.67, 136.40 +/- 18.15, 138.40 +/- 22.20, respectively. ET decreased from 181.68 +/- 5.10, 181.27 +/- 4.76, 181.04 +/- 4.19 to 140.55 +/- 3.01, 150.51 +/- 2.22, 161.02 +/- 3.76, respectively. CRP decreased from 41.63 +/- 7.37, 44.83 +/- 7.80, 42.06 +/- 7.21 to 28.62 +/- 5.45, 30.00 +/- 10.73, 37.09 +/- 4.94, respectively. ICAM-1 decreased from 225.77 +/- 11.96, 222.78 +/- 14.46, 225.17 +/- 10.03 to 190.93 +/- 12.67, 197.42 +/- 14.56, 200.64 +/- 15.36, respectively. VCAM-1 decreased from 566.72 +/- 24.46, 560.61 +/- 25.67, 359.61 +/- 42.75 to 506.26 +/- 37.26, 516.83 +/- 28.17, 527.02 +/- 43.47, respectively. NO had no change. CONCLUSIONS: Paeonol can protect the endothelial cells of diabetic rats.


Assuntos
Acetofenonas/farmacologia , Diabetes Mellitus Experimental/prevenção & controle , Medicamentos de Ervas Chinesas/farmacologia , Células Endoteliais/efeitos dos fármacos , Paeonia/química , Acetofenonas/administração & dosagem , Animais , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/induzido quimicamente , Relação Dose-Resposta a Droga , Medicamentos de Ervas Chinesas/administração & dosagem , Endotelinas/sangue , Endotélio Vascular/citologia , Ensaio de Imunoadsorção Enzimática , Epoprostenol/sangue , Molécula 1 de Adesão Intercelular/sangue , Masculino , Óxido Nítrico/sangue , Ratos , Ratos Sprague-Dawley , Tromboxano A2/sangue
2.
Zhong Yao Cai ; 32(11): 1720-2, 2009 Nov.
Artigo em Chinês | MEDLINE | ID: mdl-20218297

RESUMO

OBJECTIVE: To observe the effects of Danhong injection on experimental atherosclerosis rabbits and explore its possible mechanism. METHODS: Forty New-Zealand male rabbits were randomly divided into four groups: normal control group, high-cholesterol group, danhong injection group and aspirin group, all rabbits were administered for fourteen weeks. The plaque area of aorta in each group was determined by image analysis. The blood lipid level was tested by ELISA method, malonaldehyde (MDA) in aorta wall was analyzed with thiobarbituric acid method, the iNOS and COX-2 in aorta wall was tested with RT-PCR method. RESULT: There were significant difference between danhong injection group and other groups (P < 0.5), danhong injection and Aspirin decreased the TG, TC and LDL-C level in plasma of rabbit model and decreased the expression of inflammatory cytokines and the oxidative stress level in aorta wall. CONCLUSION: Danhong injection can inhibit the formation of experimental atherosclerosis in rabbits, which may be related to decreasing blood lipid, plaque inflammation and oxidative stress level.


Assuntos
Aorta/efeitos dos fármacos , Aterosclerose/tratamento farmacológico , Medicamentos de Ervas Chinesas/farmacologia , Fitoterapia , Animais , Aorta/metabolismo , Aorta/patologia , Aspirina/farmacologia , Aspirina/uso terapêutico , Aterosclerose/metabolismo , Aterosclerose/prevenção & controle , Carthamus tinctorius/química , Colesterol/sangue , Modelos Animais de Doenças , Combinação de Medicamentos , Medicamentos de Ervas Chinesas/química , Medicamentos de Ervas Chinesas/uso terapêutico , Injeções , Masculino , Malondialdeído/metabolismo , Óxido Nítrico Sintase/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Coelhos , Distribuição Aleatória , Triglicerídeos/sangue
3.
Zhong Yao Cai ; 31(3): 470-2, 2008 Mar.
Artigo em Chinês | MEDLINE | ID: mdl-18619256

RESUMO

OBJECTIVE: To observe the therapeutic and prognostic effects and to evaluate the safety of Zhi-Xin-Fang on heart failure resulting from cardiomyopathy. METHODS: 62 patients with cardiomyopathy combined with heart failure were treated with standard western medical therapy as treatment group. The other 60 patients with the same diseases were administered with both Zhi-Xin-Fang and standard western medicines as control. Several parameters were observed to evaluate the effect of Zhi-Xin-Fang on the heart failure, containing the therapeutic effect of clinical symptom and physical signs, the improvement of heart function and the ultrasonic caridogram. We also observed the effect of Zhi-Xin-Fang to relieve the clinical symptom and improve the heart function and quality of life and prognosis. RESULTS: As the NYHA classify for heart failure, the effective rate for the treatment group was 95% , more effective than the control group (effective rate: 80.65%) (P<0.05). There was significant improvement for LVEF and LVDS for both groups. However, the treatment group was better than the control group (P<0.05). The clinical symptom was significantly improved compared to the untreatment in both groups. The treatment group was better than the control group for effective rate (P<0.05) but not for the total effective rate. There was no significant difference for the function of liver and kidney, blood routine method, electrolyte compared to before for the two groups. CONCLUSION: The standard western medicines combined with Zhi-Xin-Fang is a good therapy for treating heart failure resulting from cardiomyopathy. The combined therapy can relieve the cinical symptom of heart failure, improve the heart function and quality of life. It is also safer for the patients. However, its long-term prognosis should be further studied in the future.


Assuntos
Cardiomiopatias/complicações , Medicamentos de Ervas Chinesas/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Fitoterapia , Adulto , Idoso , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Quimioterapia Combinada , Medicamentos de Ervas Chinesas/farmacologia , Feminino , Insuficiência Cardíaca/etiologia , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Volume Sistólico/efeitos dos fármacos , Resultado do Tratamento , Adulto Jovem
4.
Zhong Yao Cai ; 30(6): 687-90, 2007 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-17918442

RESUMO

OBJECTIVE: To study the effect of Paeonol on PGI2, TXA2, ET and NO in diabetic rats. METHODS: Streptozocin was used on rats to make diabetic animal models. Different dosage of Paeonol were used on diabetic animal models. PGI2, TXA2, ET and NO were tested after 30 days therapy. RESULTS: Compared with those in the control group, the level of PGI2 increased and the contents of TXA2 and ET decreased in treatment group. Among them, the high dosage group was more obvious (P < 0.01). But the level of No Had no change. CONCLUSION: Paeonol can decrease the ET and TXA2 in diabetic rats, and increase PGI2 in diabetic rats.


Assuntos
Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/prevenção & controle , Medicamentos de Ervas Chinesas/farmacologia , Paeonia/química , Animais , Glicemia/análise , Diabetes Mellitus Experimental/induzido quimicamente , Relação Dose-Resposta a Droga , Medicamentos de Ervas Chinesas/uso terapêutico , Endotelinas/sangue , Epoprostenol/sangue , Masculino , Óxido Nítrico/sangue , Fitoterapia , Casca de Planta/química , Raízes de Plantas/química , Ratos , Ratos Sprague-Dawley , Estreptozocina , Tromboxano A2/sangue
5.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 26 Suppl: 88-92, 2006 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-17569358

RESUMO

OBJECTIVE: To observe the effect of drug-containing serum of Chinese traditional herbal decoction Weikangning (WKN) on growth of gastric cancer cell, expression of vascular endothelial growth factor (VEGF) and its receptors including KDR and Flt-1. METHODS: A total of 120 male Wistar rats were given high, medium and low-dose WKN. After the drug-containing serum was prepared, the gastric cancer cells MGC-803 of different dose groups were cultured with the drug-containing serum, respectively. The gastric cell growth was observed by using light microscope and flow cytometer,the expression of VEGF and its receptor Flt-1 was detected with SABC immunohistochemistry method and the mRNA expression levels of VEGF and its receptors including KDR and Flt-1 of different groups were detected with reverse transcription-polymerase chain reaction (RT-PCR), respectively. RESULTS: The gastric cancer cell growth and cell cycle of the three medicated groups were significantly improved as compared with those of the control group (P <0. 01) ,the proportion of cells in G0 - G1 phase was increased,while the cells in S phase were decreased. It was shown that the apoptotic rates were increased in the medicated groups in a dose-dependent manner. The gray scales ( microm(2) ) of VEGF and Flt-1 in high, medium and low dose groups was 182. 44 +/-0. 54,178. 65 +/-0. 56,174. 80 +/-0. 81 and 168. 51 +/- 0. 81,162. 01 +/-0. 52,148. 20 +/-0. 69, respectively vs 147.82 +/-0. 15(P <0.01) and 144.31 +/-0.71 (P <0.01) in the control group. The mRNA expression of VEGF and its receptors significantly decreased in gastric cancer cells after cultured with WKN contained serum (P < 0. 01 ). CONCLUSION: WKN has inhibitory effects on gastric cancer cell growth and mRNA expression of VEGF as well as its receptors KDR and Flt-1.


Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Medicamentos de Ervas Chinesas/uso terapêutico , Neoplasias Gástricas/tratamento farmacológico , Fator A de Crescimento do Endotélio Vascular/metabolismo , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/metabolismo , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo , Animais , Antineoplásicos Fitogênicos/farmacologia , Ciclo Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Medicamentos de Ervas Chinesas/farmacologia , Masculino , Ratos , Ratos Wistar , Neoplasias Gástricas/enzimologia , Neoplasias Gástricas/metabolismo
6.
World J Gastroenterol ; 11(7): 938-42, 2005 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-15742392

RESUMO

AIM: To observe the effect of Chinese traditional herbal decoction Weikang-ning (WKN) on cell growth and expression of VEGF and its receptors KDR and Flt-1 in gastric cancer cell line MGC-803. METHODS: A total of 120 male Wistar rats were divided into control group, high dose, medium dose and low dose groups fed with natural saline, 20, 10, and 5 g/kg of WKN, respectively. The experimental animals were finally killed for the preparation of drug-containing serum. The gastric cancer cell MGC-803 was cultured with the drug-containing serum drawn from the rats in different groups. We observed the growth condition of the cancer cells with light microscope and flow cytometer. The expression of mRNA of VEGF and its receptors KDR and Flt-1 was detected with RT-PCR. RESULTS: The proportion of cells in G(0)-G(1) phase was (65.40+/-0.41)%, (56.92+/-0.62)%, (55.89+/-0.69)% in high, medium and low dose groups respectively vs (41.35+/-0.55)% in control group (P<0.01), while the cells in G(2)-S and S phases were (11.62+/-0.62)% and (22.99+/-0.69)%, (17.08+/-0.80)% and (26.00+/-0.71)%, (19.37+/-0.57)% and (24.74+/-0.64)% in high, medium and low dose groups, respectively, vs (23.65+/-0.56)% and (35.00+/-0.60)% in control group (P<0.01). The expression of mRNA of VEGF and its receptors was significantly decreased, the area of electrophoresis bands (AREA), the absorptivity of mean optical density (A) and the product of AREA and A were significantly lower in WKN-administered groups than that in control group (P<0.01). CONCLUSION: The decoction of WKN suppresses the growth of gastric cancer cell MGC-803 and decreases the expression of mRNA of both VEGF and its receptors KDR and Flt-1.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Neoplasias Gástricas/tratamento farmacológico , Fator A de Crescimento do Endotélio Vascular/genética , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/genética , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/genética , Animais , Divisão Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , RNA Mensageiro/análise , Ratos , Ratos Wistar , Neoplasias Gástricas/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...